Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
March 26, 2024 06:30 ET
|
Praxis Precision Medicines, Inc.
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with...
Praxis Precision Medicines to Host PRAX-628 Program Update
March 25, 2024 16:01 ET
|
Praxis Precision Medicines, Inc.
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at...
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
October 02, 2023 13:17 ET
|
Praxis Precision Medicines, Inc.
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for...
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
August 07, 2023 07:00 ET
|
Praxis Precision Medicines, Inc.
Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in the composite qEEG measured through 10-day treatment period Ongoing PRAX-628 Phase 2 Photo-Paroxysmal...
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
June 22, 2023 07:00 ET
|
Praxis Precision Medicines, Inc.
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to...
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
May 11, 2023 06:55 ET
|
Praxis Precision Medicines, Inc.
PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider...